Ashish Kumar

Dr. Ashish Kumar


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2024 in Cells
Verified
Journal Article
Open access
PDF file
SKSaif Khan
Saif Khan
SJSuresh Babu Jandrajupalli
Suresh Babu Jandrajupalli
NBNashwa Zaki Ali Bushara
Nashwa Zaki Ali Bushara
RRRama Devi Patel Raja
Rama Devi Patel Raja
SMSHADAB MIRZA
SHADAB MIRZA
MLMohtashim Lohani
Mohtashim Lohani
Advanced triple-negative breast cancer (TNBC) has poorer outcomes due to its aggressive behavior and restricted therapeutic options. While therapies like checkpoint inhibitors and PARP inhibitors offer some benefits, chemotherapy remains ineffective beyond the first line of treatment. Antibody–drug conjugates (ADCs) like sacituzumab govitecan-hziy (SG) represent a significant advancement. SG combines SN-38, an irinotecan derivative, with a Trop-2-targeting antibody via a pH-sensitive linking moiety, achieving a good drug:antibody ratio. In a phase I-II study involving metastatic TNBC (mTNBC) individuals, SG achieved an overall response rate of 33.3% and a median response period of 7.7 months. The phase III ASCENT trial demonstrated SG’s efficacy in relapsed or refractory TNBC, improving median progression-free survival and median overall survival compared to chemotherapy. Common side effects include neutropenia, nausea, and fatigue. This article highlights the clinical potential, pharmacokinetics, safety profile, and resistance mechanisms of SG along with key ongoing clinical trials, emphasizing its role in managing refractory mTNBC, especially in third-line therapy. The review also discusses current strategies for managing adverse reactions and sequencing ADC treatments in clinical practice, along with the predicted basis of resistance. The optimal sequencing of SG relative to other ADCs, such as trastuzumab deruxtecan or T-DXd, remains an evolving question, especially as newer agents with distinct mechanisms of action and safety profiles enter the field. Further research is essential to establish evidence-based strategies for sequencing SG and addressing disease progression post-ADC therapy.

23 January 2025 in Results in Surfaces and Interfaces
Verified
Journal Article
Open access
DSD. Sriram
D. Sriram
BSB.D.Y. Sunil
B.D.Y. Sunil
SJS. Jeyakrishnan
S. Jeyakrishnan
CRC. Rakesh
C. Rakesh
SVS. Vijayakumar
S. Vijayakumar
LSLakshita Sehgal
Lakshita Sehgal

25 March 2024 in E3S Web of Conferences
Verified
Conference Paper
Open access
PDF file
VAV Alekhya
V Alekhya
SBSwathi B
Swathi B
AKAshish Kumar
Ashish Kumar
AKAshwani Kumar
Ashwani Kumar
SJSonali Jayronia
Sonali Jayronia
AAAhmed Salam Abood
Ahmed Salam Abood
This proceeding volume has been retracted from the publication because we found some solid reasons to believe that it has infringed our integrity criteria and now presents a risk for our journal and scholarly science in general. Different types of malpractice are involved, in particular citation manipulation and inappropriate references. We are extremely concerned by such malpractice which considerably impacts the image of our title and our Publisher’s reputation. For further details, please refer to our publishing ethics policies. If you have any questions, please contact us at contact@webofconferences.org See the retraction notice E3S Web of Conferences 505, 00001 (2024), https://doi.org/10.1051/e3sconf/202450500001

2 July 2024 in International Journal on Interactive Design and Manufacturing (IJIDeM)
Verified
Journal Article
Closed access
PDF file
DNDHARAVATHU NARESH
DHARAVATHU NARESH
APAlluri Sujatha Priyadarshini
Alluri Sujatha Priyadarshini
RRRamesh Raju
Ramesh Raju
VSVinothkumar Sivalingam
Vinothkumar Sivalingam
VRV. Revathi
V. Revathi
AKAshish Kumar
Ashish Kumar

5 November 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
SKSaif Khan
Saif Khan
SJSuresh Babu Jandrajupalli
Suresh Babu Jandrajupalli
NBNashwa Zaki Ali Bushara
Nashwa Zaki Ali Bushara
RRRama Devi Patel Raja
Rama Devi Patel Raja
KSKuldeep Sharma
Kuldeep Sharma
MLMohtashim Lohani
Mohtashim Lohani
Advanced triple-negative breast cancer (TNBC) has poorer outcomes due to its aggressive behaviour and limited treatment options. While therapies like checkpoint inhibitors and PARP inhibitors (PARPi) offer some benefit, chemotherapy remains ineffective beyond the first line of treatment. Antibody-drug conjugates (ADCs) like sacituzumab govitecan-hziy (SG) represent a significant advancement. SG combines SN-38, an irinotecan derivative, with a TROP-2-targeting antibody via a pH-sensitive linking moiety, achieving an good drug:antibody ratio. Infused on Days 1 and 8 over 21 days, SG utilizes a moderately stable linker to ensure effective tumor targeting while minimizing side effects like diarrhea. By delivering SN-38 into the tumor niche, it induces double-stranded DNA damage, promoting cancer apoptosis. In a phase I-II study involving 108 mTNBC patients, SG achieved an overall response rate (ORR) of 33.3% and a median response period of 7.7 months. Common side effects included neutropenia, nausea, and fatigue. This review highlights clinical potential, pharmacokinetics, safety profile, resistance mechanisms of SG along with key ongoing clinical trials, emphasizing its role in managing refractory mTNBC, especially in third-line therapy.

19 May 2025 in BioNanoScience
Verified
Journal Article
Closed access
PDF file
MAMadhukriti
Madhukriti
ARArpita Roy
Arpita Roy
Soumya PanditSoumya Pandit
Soumya Pandit
AKAshish Kumar
Ashish Kumar
KSKuldeep Sharma
Kuldeep Sharma
HSHendrix Setyawan
Hendrix Setyawan